Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress aXess graft demonstrated excellent patency, low rates of infection and re-intervention Data indicates a significant improvement in performance compared to standard hemodialysis access treatment EINDHOVEN, The Netherlands – 28 April 2023, Xeltis, a developer […]